For a modestly-sized diagnostics stock, Exact Sciences (NASDAQ:EXAS)
seems to generate an above-average level of animated response (I'd say
"discussion", but a quick look at the comments section of EXAS articles
shows less discussion and more squabbling). I have often found that
controversy can mean opportunity, as it often reflects wildly divergent
viewpoints, and I continue to believe that is the case with Exact
Sciences.
My thesis in brief - the Cologuard works, is a
meaningful step forward in the detection, prevention, and treatment of
colorectal cancer, and will be reimbursed at a rate that allows Exact
Sciences to earn solid profits, though likely not as quickly as some on
the Street expect. I believe these shares can trade into the high teens
with an FDA approval and favorable coverage decision, and I expect the
second half of this year to be a pretty active period for the company
and stock.
Follow this link to the full article:
Amidst Ongoing Doubts, Exact Sciences Still Offers Opportunity
No comments:
Post a Comment